Cancer Risk Assessment Tests in India Analyzed

Zydus Lifesciences has partnered with Myriad Genetics to bring advanced cancer risk assessment tests to India. This collaboration aims to help people understand their chances of developing cancer and make informed decisions about their health. Myriad Genetics is a company known for creating tools that use genetic information to diagnose and treat diseases.

• Zydus & Myriad Genetics: New cancer test partnership.
• Tests identify cancer risk through genetic analysis.
• Tests aid in personalized cancer treatment pathways.
• MyRisk and MyChoice HRD Plus: Key diagnostic tools.
• Prolaris assesses prostate cancer progression, prognosis.
• Cutting-edge technology empowers Indian oncologists.

The agreement focuses on introducing specific Myriad Genetics tests to the Indian market. These tests – including MyRisk Hereditary Cancer Test, MyChoice HRD Plus, and Prolaris – offer a detailed look at a person’s genetic makeup and their potential risk of developing cancer. These tests are widely used in other parts of the world and offer valuable information to doctors and patients.

For patients with prostate or ovarian cancer, the Prolaris Test and MyChoice HRD Plus Test, respectively, are designed to track how the cancer is moving and inform the best treatment options. The Prolaris Test, for example, analyzes gene expression to predict the progression of prostate cancer, while the MyChoice HRD Plus Test focuses on ovarian cancer.

Zydus Lifesciences will be responsible for marketing, educating doctors, and making these tests available to patients across India. This partnership brings access to advanced genomic decision-support tools to a significant population.

“Early detection and tailored treatment strategies are crucial for improving cancer outcomes.”